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926 Hosking et alA 42-year-old man presented with a 3-month history of persistent ulcerated nodules (Fig 1). Historywas relevant
for deployment to the Middle East, Africa, Turkey, and South East Asia. He also reported skinning squirrels and
butchering hogs on his farm in Missouri. Review of systems found intermittent fevers and night sweats. Prior
treatment included multiple oral antibiotics without improvement. Examination found ulcerated, firm, pink
nodules on the right forearm, elbow, and arm in sporotrichoid distribution without palpable lymphadenopathy.
A punch biopsy was obtained and staining performed, including hematoxylin-eosin (Fig 2, A), CD30 (Fig 2, B),
anaplastic lymphoma kinase (ALK-1) (Fig 2, C; control, Fig 2, D).Question 1: What is your diagnosis?
A. Bacillus anthracis
B. Leishmaniasis
C. Lymphomatoid papulosis (LyP)
D. Primary cutaneous anaplastic large cell lym-
phoma (PC-ALCL)
E. Tularemia
Answers:
A. Bacillus anthracis e Incorrect. B anthracis
is a spore-forming, toxin-producing bacteria
found in soil. Risk factors for cutaneous anthrax
include living in Turkey (endemic area) and
butchering meat (mainly cows, also reported in
pigs). However, ulcerations rapidly progress to
eschars, and a CD301 infiltrate would not be
observed. Gram stain would find spore-forming
rods.
B. Leishmaniasis e Incorrect. Infection with Leish-
mania results in a papule or nodule with central
ulceration at the site of a sandfly bite. Although the
patient has risk factors for exposure to Old World
leishmaniasis, geographically distributed from West
Africa to Central Asia, histopathology would show
Leishmania amastigotes within histiocyte
cytoplasm.1
C. LyP e Incorrect. LyP presents as recurrent
crops of small papulonodules. Although LyP is on
the spectrum of CD301 lymphoproliferative disor-
ders, lesions classically resolve and reoccur over
weeks to months. Histopathology for type A LyP
reveals a wedge-shaped dermal infiltrate of CD301
lymphoid cells with numerous neutrophils and
eosinophils.2
D. PC-ALCL e Correct. PC-ALCL presents as a
solitary tumor or several grouped papules/-
nodules. Histopathology shows diffuse dermal
infiltration of CD301/ALK-1- atypical mononu-
clear cells with hyperchromatic horseshoe-
shaped nuclei, numerous mitoses, and apoptotic
bodies.2E. Tularemia e Incorrect. Tularemia is caused by
the gram-negative coccobacillus Francisella tular-
ensis. Although rabbits most commonly transmit
tularemia, squirrels can also be infected. The ulcer-
oglandular form presents with a papule that pro-
gresses to an ulcer with eschar formation.
Histopathology shows suppurative granulomatous
inflammation and would not show a CD301
lymphoid infiltrate.
Question 2: Which of the following immuno-
histochemical markers would indicate that the
diagnosis is likely systemic rather than primary
cutaneous?
A. Negative CD56
B. Negative epithelial membrane antigen (EMA)
C. Positive ALK-1
D. Positive B-cell lymphoma 2 (Bcl-2)
E. Positive cutaneous lymphocyte antigen (CLA)
Answers:
A. Negative CD56 e Incorrect. CD56 is expressed
in 12% to 75% of PC-ALCL and is positive in systemic
ALCL and therefore does not help differentiate
between these 2 entities.2
B. Negative EMA e Incorrect. EMA is typically
negative in PC-ALCL and positive in systemic ALCL.2
C. Positive ALK-1 e Correct. Positive ALK-1
would indicate that the ALCL is more likely sys-
temic, as the t(2;5) gene rearrangement involving
the ALK gene is an extremely rare event in PC-ALCL
compared with nearly 60% of all systemic ALCL.
ALK-1 can help differentiate the 2 entities in inde-
terminate cases.2
D. Positive Bcl-2 e Incorrect. Bcl-2 does not help
differentiate between these 2 entities, as it is positive
in 30% of PC-ALCL and is positive in systemic
ALCL.2
E. Positive CLA e Incorrect. Most cases of PC-
ALCL express CLA, whereas CLA is negative in
systemic ALCL.2
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is US Food and Drug Administration (FDA)-
approved for the treatment of this condition?
A. Bexarotene gel
B. Brentuximab vedotin (BV)
C. Imiquimod
D. Interferon
E. Methotrexate
Answers:
A. Bexarotene gel e Incorrect. Bexarotene is FDA
approved for the topical treatment of cutaneous
lesions in patients with cutaneous T-cell lymphoma,
stage 1A and 1B, who have refractory or persistent
disease after other therapies or who have not
tolerated other therapies. Data regarding the use
of topical bexarotene gel are limited to case reports
and the control arm of the ALCANZA trial in which
the response rate was low.3
B. BV e Correct. BV is an anti-CD30 monoclonal
antibody that is FDA approved for the treatment of
adult patients with PC-ALCL who have received at
least 1 prior systemic therapy.4 Approval was based
on a phase 3, randomized clinical trial (ALCANZA),
which randomized patients to receive BV or either
methotrexate or bexarotene. BV resulted in com-
plete resolution of skin involvement in 10 of 16
patients (63%) with PC-ALCL.3
C. Imiquimod e Incorrect. The use of topical
imiquimod has been described in case reports and
case series; however, it is not FDA approved for PC-
ALCL.5
D. Interferon e Incorrect. Interferon is not FDA
approved for PC-ALCL, and because of its toxicity, it
is generally reserved for patients who progress on or
who are intolerant to methotrexate or bexarotene.E. Methotrexate e Incorrect. Methotrexate is not
FDA approved for PC-ALCL. However, low-dose
(less than 25 mg/wk) is considered first-line therapy
for multifocal PC-ALCL when radiotherapy is not
feasible.2
Patient Course: The patient underwent local radia-
tion to the right arm, which he tolerated well, but
new lesions developed proximal to the radiated port.
Thus, he was started on brentuximab for 4 cycles and
experienced complete remission.Abbreviations used:
ALCL: anaplastic large cell lymphoma
ALK: anaplastic lymphoma kinase
Bcl-2: B-cell lymphoma 2
BV: brentuximab vedotin
CLA: cutaneous lymphocyte antigen
EMA: epithelial membrane antigen
FDA: US Food and Drug Administration
PC-ALCL: primary cutaneous anaplastic large cell
lymphoma
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